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Abstract
Background: Autoimmune diabetes (T1D) onset is preceded by a long inflammatory process directed against the
insulin-secreting β cells of the pancreas. Deciphering the early autoimmune mechanisms represents a challenge due to
the absence of clinical signs at early disease stages. The aim of this study was to identify genes implicated in the early
steps of the autoimmune process, prior to inflammation, in T1D. We have previously established that insulin
autoantibodies (E-IAA) predict early diabetes onset delineating an early phenotypic check point (window 1) in disease
pathogenesis. We used this sub-phenotype and applied differential gene expression analysis in the pancreatic lymph nodes
(PLN) of 5 weeks old Non Obese Diabetic (NOD) mice differing solely upon the presence or absence of E-IAA. Analysis
of gene expression profiles has the potential to provide a global understanding of the disease and to generate novel
hypothesis concerning the initiation of the autoimmune process.
Methods: Animals have been screened weekly for the presence of E-IAA between 3 and 5 weeks of age. E-IAA positive
or negative NOD mice at least twice were selected and RNAs isolated from the PLN were used for microarray analysis.
Comparison of transcriptional profiles between positive and negative animals and functional annotations of the resulting
differentially expressed genes, using software together with manual literature data mining, have been performed.
Results: The expression of 165 genes was modulated between E-IAA positive and negative PLN. In particular, genes
coding for insulin and for proteins known to be implicated in tissue remodelling and Th1 immunity have been found to
be highly differentially expressed. Forty one genes showed over 5 fold differences between the two sets of samples and
30 code for extracellular proteins. This class of proteins represents potential diagnostic markers and drug targets for
T1D.
Conclusion: Our data strongly suggest that the immune related mechanisms taking place at this early age in the PLN,
correlate with homeostatic changes influencing tissue integrity of the adjacent pancreatic tissue. Functional analysis of the
identified genes suggested that similar mechanisms might be operating during pre-inflammatory processes deployed in
tissues i) hosting parasitic microorganisms and ii) experiencing unrestricted invasion by tumour cells.
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Background
Type 1 diabetes (T1D) is an autoimmune disease charac-
terized by the absence of insulin due to the specific
destruction of the insulin-producing β cells of the pancre-
atic islets. This is a progressive process taking over 20
weeks in the NOD mouse and several years in human
patients to be completed [1]. The NOD animal model has
been a valuable source of information for several aspects
of disease pathogenesis [2]. Genetic studies have contrib-
uted to portray the complexity of the disease and have
established that multiple loci are carrying genes impli-
cated in T1D in human [3] and animal models [4]. In
human, more than 6 genes contribute to the disease [5,6]
while over 20 loci have been described in the NOD mouse
[7] but only few possible candidate genes have been une-
quivocally defined [8] other than the H2g7 Idd1  locus
[7,9].
Despite intensive research, the initial causal events remain
elusive since the selection of individual mice at early
stages, prior to the overt clinical signs, represents a chal-
lenge. Indeed, even though the NOD mice are inbred not
all animals develop the disease, with an incidence of 40-
90% in females, depending on the colony [2]. Additional
hindrances for selecting individual animals that will sub-
sequently develop the disease with certainty are the low
penetrance of the implicated genes and the influence of
environmental factors. For these reasons, the exact mech-
anisms taking place prior to the onset of the pancreatic
islet-damaging sustained inflammatory processes remain
largely unknown.
The aim of our investigation was to evaluate the possibil-
ity of the existence of distinct gene expression profiles in
order to eventually render possible the study of the early
molecular changes, taking place before the onset of
inflammation in autoimmune prone mice. One hypothe-
sis is that during the post-weaning period in genetically
autoimmune prone individuals (mouse or human),
homeostatic changes prompt the immune system not to
conform to physiological responses, but to instead trigger
pathways that lead to the final autoimmune condition in
later life. Exogenous factors including the more or less sus-
tained presence of micro-organisms in otherwise
microbe-free tissues may take place during early life stages
[10]. This may influence the immune regulatory processes
put in place to prevent, attenuate and/or repair the acute
or sustained inflammation. It has been reported that early
immune stimulation prevents autoimmune diseases,
while infections later in life might exacerbate their advent
in genetically prone individuals [11]. A single injection of
BCG (the Mycobacterium bovis vaccine strain) is highly pro-
tective against T1D in the NOD mice [12] and BB rats [13]
when administered early but it has no beneficial effect
given after disease onset; similar to what has been
observed in human [14]. These observations lead to the
indication that the time "window" of opportunity to pre-
vent disease in human may share similarities with the
NOD mice and thus BCG or other immune-system signal-
ling, safe biological preparation, should be given as ther-
apy before the onset of inflammation of the pancreatic
islets (insulitis). This early "window" coincides in the
NOD mouse model with the early appearance of insulitis,
occurring between 4 and 7 weeks [2] and led to the
hypothesis that early initiating mechanisms should be
evaluated at this age i.e. over the weaning period. We have
previously established that IAA are present early between
3 and 5 weeks of age and represent a diabetes sub-pheno-
type since their presence in NOD mouse sera, at this early
period, correlated with the final disease phenotype [15].
Thus Early-IAA (E-IAA) have been shown to mark the first
measurable phenotypic checkpoint in T1D pathogenesis.
Animals positive for E-IAA at 3-5 weeks after weaning,
develop autoimmune diabetes earlier (between 16 and 20
weeks) than their E-IAA negative littermates [15]. We have
used this E-IAA sub-phenotype to select individual mice as
diabetes prone and search for changes in gene expression
patterns in the PLN, correlating with the presence of E-IAA
in the NOD mouse sera.
Overt T1D is considered to require the dominant presence
of islet-destructive pro-inflammatory T lymphocytes [16].
The onset of T cell activation is known to deploy within
organized secondary lymphoid tissues, draining the tissue
that delivers the adequate signals for activation of T and B
lymphocytes.
In the NOD mice, any early islet-disruptive remodelling
process taking place, whether it implies β cell apoptosis or
repair mechanisms [17], might result in delivery of
immune cell-signalling to the PLN. The endpoint of such
signalling might include deletion of autoreactive regula-
tory T cells, and/or expansion of autoreactive pro-inflam-
matory T lymphocytes as well as T cell-dependent
autoreactive B lymphocytes. The later further differentiate
as insulin auto-antibody secreting plasma cells [18]. Anti-
gen specific T cells interact with dendritic cells (DC)
within intact explanted lymph nodes (LN), and it has
been observed that immunological synapse formation
and prolonged interactions between these 2 cell types is
followed by activation, dissociation and rapid migration
of T cells away from the antigenic stimulus area [19]. Even
more strikingly, excision of PLNs at 3 weeks of age pro-
tects NOD mice against IAA, insulitis and diabetes devel-
opment, almost completely, but has no effect when
performed at 10 weeks of age [20]. Therefore the time
frame of 3 to 5 weeks seems to correspond to the initia-
tion of the autoimmune process in the PLN and the
related transcriptional profiling can be potentially sort out
in this tissue.BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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We anticipated that at 5 weeks of age, differential gene
expression correlated with the presence or absence of E-
IAA, in the PLN of NOD mice, could be detected. This tim-
ing allowed for prior tests of E-IAA at 3 and 4 weeks. We
used microarray analysis to determine gene expression
patterns in the PLN. This approach has the potential i) to
provide a global profiling of the modulated genes at this
first measurable phenotypic checkpoint in T1D pathogen-
esis, ii) to allow novel hypothesis to be formulated con-
cerning the initiation of the islet-destructive autoimmune
process and eventually to further challenge these hypoth-
esis. We identified ectopic high expression of insulin
genes in the E-IAA positive PLN. This data confirm the
possible cross talk between the pancreas and its adjacent
lymph nodes via at least one pancreas specific autoanti-
gen.
Functional annotations of up-regulated transcripts in the
PLN of E-IAA positive NOD mice revealed a gene network
otherwise found also to operate during inflammatory and
tumour processes. Furthermore, we have identified several
transcripts coding for extracellular proteins that have to be
evaluated as potential disease pathogenesis associated
markers and possibly therapeutic targets. This data repre-
sent a "freeze frame" of a first identifiable disease check
point, associated with the presence of IAA and corre-
sponding to the early steps of the autoimmune process.
Methods
Animals
Mice were purchased from Taconic farms (NOD/tac).
Pregnant females were tested one week before delivery for
the presence of IAA. To discard any possibility of trans-
placental antibodies affecting our experimental design,
based upon the spontaneous appearance of IAA, we have
used, when possible, individual mice from progenies of
negative females and from litters that they contained both
positive and negative individuals.
Animals were tested as previously described [15], at 3, 4
and 5 weeks of age for the presence of IAA. PLN of IAA
positive and negative animals were used for RNA prepara-
tion and pancreata have been also isolated for histology.
All animals were kept under SPF conditions and all stud-
ies were performed under the recommended Laboratory
Animal Care committee of the University of Colorado.
IAA assay
IAA were measured in a standard radioimmunoassay as
previously described [15,21] incorporating competition
with unlabeled insulin and precipitation with Protein A/
G sepharose in a 96 well filtration plate.
Histology immunoassay
Tissues were formalin (10%) fixed and embedded in par-
affin. Sections of paraffin-embedded tissues were stained
with Hematoxylin & Eosin and with polyclonal guinea pig
anti-insulin antibodies (Millipore) followed by incuba-
tion with a peroxidase-labeled anti-guinea pig IgG anti-
body (Kierkegaard & Perry Laboratories Inc.). The
presence of insulitis has been evaluated by visualizing
more than 10 islets in 3 different sections from the same
individual. Similarly the presence of insulin expressed in
the PLNs has been evaluated in more than 3 sections of
each individual tissue.
Tissues and RNA preparation
PLN have been dissected from six E-IAA negative and
three E-IAA positive animals at 5 weeks of age. Tissues
were immediately placed in RNA later containing RNases
inhibitors (Qiagen) and processed for total RNA prepara-
tion on the same day with Qiagen mini-RNA commercial
kits (RNeasy) with on-column DNase treatment following
the manufacturer's protocol. Quantity, purity and integ-
rity were confirmed initially by spectrophotometry (A260/
A280 ratio) and capillary electrophoresis (2100 Bio ana-
lyzer; Agilent Technologies, Palo Alto, CA). 4.5 μg of total
RNA were used for the target preparations and no addi-
tional step of cDNA amplification has been used in our
studies.
Microarray Analysis
Target preparations and chip hybridizations have been
performed as recommended by the manufacturer
MG_U74A_version 2 GeneChips (Affymetrix, Santa Clara,
Ca). Each chip contained 12 486 probe sets (Supplemen-
tal Materials and Methods). All gene expression data dis-
cussed in this report have been deposited in NCBI's Gene
Expression Omnibus [22] and are accessible through GEO
Series accession number GSE15582 http://
www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE15582.
Chromosomal location enrichment by Map genes to 
chromosomes
Genes used for hierarchical clustering have been also used
to create the Genome view of our transcriptome data by
using the dChip software (map of genes tool), as
described in the dChip site http://www.dchip.org.
P-values have been calculated for all stretches containing
≤20 selected genes to assess the statistical significance of
gene proximity and the significant P-values have been
reported in the analysis view. The "tightness" i.e. the rank
distance of the genes on the two ends of the stretch was
calculated by/n genes against that of n genes randomly
put on the chromosome as described http://biosun1.har
vard.edu/complab/dchip/map%20chromosome.htm.BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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Functional annotations
Gene Ontology analysis was carried out using DAVID
NIAID/NIH online functional annotation tool and ontol-
ogy terms were retained according to the significance of P-
values for any particular GO term. This indicated that
there were more genes associated with this GO term than
would be expected by random chance [23]. The results
were independently confirmed by applying the GO
Browser tool in NetAffx to the same set of differentially
expressed genes. The associations between altered genes
or pathways were further evaluated using the Ingenuity
Pathways Analysis software (IngenuityR Systems).
Reverse transcription-coupled real-time PCR
Total RNAs from PLN of E-IAA positive and negative mice
were used for Real Time PCR following the ABI software
and method. To confirm gene expression levels identified
in the arrays by RT-PCR, RNAs were aliquoted from the
same samples used for the array hybridizations.
Sequences corresponding to the investigated genes have
been retrieved from the public database and aligned with
Affymetrix target sequences using BLAST software http://
blast.ncbi.nlm.nih.gov/Blast.cgi. Primers and TaqMan
probes [see Additional File 1] have been designed using
the proprietary TaqMan software. We verified that the
amplified fragments corresponded to the exact Affymetrix
sequences. mRNA from an insulinoma cell line has been
used as positive control and 18S rRNA for data normaliza-
tion.
Results
E-IAA as a marker of autoimmune-related modifications in 
the PLN of NOD mice
We have established the following criteria for the selection
of individual mice: autoimmune positive animals have
been tested at 3, 4 and 5 weeks for the presence of IAA in
the serum and selected when positive at least twice [24].
Negative phenotype has been considered when animals
were negative for IAA at the same ages. A total of 9 animals
have been selected, 6 negative for E-IAA and 3 E-IAA pos-
itive (Table 1). Even though the presence of E-IAA have
been demonstrated to be an early marker of autoimmune
diabetes, animals negative for IAA throughout their life
may develop T1D, yet this remains a rare event (1 animal/
15) [25]. In human, some cases of IAA long term positive
individuals who do not develop T1D have been observed
[26]. As seen on Table 1, regardless of the sub phenotypic
attribution to the individual mice used in this study, one
E-IAA negative sample (A36.4) was grouped, by clustering
analysis, together with the E-IAA positive group, accord-
ing to gene expression patterns (see below). This observa-
tion underlines the complexity of the autoimmune
condition and indicates that the balance between patho-
genic and physiological immune responses controls the
outcome of disease. One possible explanation for the
absence of E-IAA in the A36.4 PLN sample is that the
selected sub-phenotype marks the disease stage without
being per se the cause for the expression patterns identi-
fied. Therefore the initiation of the autoimmune process
might be dependent upon the identified gene signatures
and independent of the presence of IAA in the serum. In
this case the E-IAA would be the consequence of an ongo-
ing mechanism but not the cause.
E-IAA related gene expression patterns in PLN
Our interest in this study was to identify gene expression
variations solely due to the presence or absence of IAA, in
a set of identical animals of the same age and same genetic
background, which however are not synchronized for the
evolution of the disease. Albeit the NOD strain is inbred,
homeostatic differences inherent to each animal might
influence the physiopathological status and in conse-
quence the disease stage. Therefore, RNAs have been pre-
pared from PLN, isolated from individual mice and used
without prior amplification. This allows identifying and
controlling for inherent biological variability of gene
expression, between individual animals that might not be
related to the E-IAA sub-phenotype and allowed us avoid-
ing the possibility for any preferential transcript amplifi-
cation.
Table 1: Subphenotypes of PLN used for transcriptome
Sample Name E-IAA Phenotype Gene expression patterns
A8.1 IAA neg NEG
A12.1 IAA neg NEG
A12.2 IAA neg NEG
A36.1 IAA neg NEG
A37.1 IAA neg NEG
A36.4 IAA neg POS
A9.6 IAA pos POS
A15.4 IAA pos POS
A15.6 IAA pos POS
Correlation of E-IAA subphenotypes with gene expression patterns as shown by unsupervised hierarchical clustering on Fig. 2.BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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The quality of whole gene expression data generated from
each of the 9 individual animals has been checked using
box plots metrics representation [see Additional File 2].
The mean fluorescence intensity values and the range of
signal amplitudes were similar across all samples and con-
sistent with a good hybridization quality of the arrays. A
scatter plot of the raw data for all transcripts of the arrays
from either E-IAA negative or positive samples clearly
showed several probe sets to be differentially expressed
between the 2 conditions (Figure 1). Expression levels for
the up-regulated genes were higher in E-IAA positive PLN,
while up-regulated variations in the E-IAA negative sam-
ples have been observed at a lower level (Figure 1).
Statistically significant differences in gene expression lev-
els between the E-IAA positive and E-IAA negative lymph
nodes were determined (adjusted P-values < 0.05 and log2
fold changes >0.42). A total of 177 probe sets were
deemed statistically significant by these criteria and corre-
sponded to 165 unique genes, whilst 12 transcripts were
identified repeatedly because they were represented on
the chip by more than one probe set [see Additional File
3]. Unsupervised hierarchical clustering of the modulated
probe sets confirmed clear sample segregation in the two
phenotypic groups (Figure 2). Gene expression patterns
correlated well with phenotypic evaluation for all individ-
ual mice except one: sample A36.4 is classified with the
positive group (Figure 2, noted by *) whilst its phenotypic
evaluation, as described above (Table 1), has identified it
as a negative sample. This discrepancy, as discussed above,
correlates with previous findings in human and the NOD
Correlation of gene expression between E-IAA positive and negative PLN Figure 1
Correlation of gene expression between E-IAA positive and negative PLN. Scatter plot representation of all 
MU74Av2 array elements (GS6.0 software), after hybridization with the RNA probes. A subset of elements that are distinct 
between the two arrays and which deviate the most in signal intensity is depicted by the colour codes: blue for the highly 
expressed in the E-IAA positive PLNs, red for the highly expressed in the E-IAA negative samples and yellow for the probe sets 
that do not show statistical significant changes between the two sets of samples in both X and Y "fluorescence intensities".
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mouse, whereas autoantibody negative individuals have
still a probability to develop the disease [25,27].
Interestingly, 77% (119 genes and 8 ESTs) of the differen-
tially expressed transcripts were up regulated in the E-IAA
samples while only 22% (34 genes and 3 ESTs) were
down regulated. The majority of the up-regulated tran-
scripts (69%, ie. 82 transcripts and 5 ESTs) have expres-
sion patterns varying over 2 fold while only 5 out of the
34 down-regulated genes and one out of the 3 ESTs (16%)
showed over 2 fold differences between the two sets of
samples [see Additional File 3].
The biological relevance of these trends in gene expression
changes will obviously need to be tested on an individual
gene basis.
Validation of microarray data by Real time PCR and 
immunohistochemistry
In order to validate the expression levels observed in the
arrays, we selected 4 genes for quantitative real time PCR
analysis (Q-RT-PCR): 2 regenerating islet-derived coding
genes, Reg2 and Reg3a (Figure 3A &3B) and the 2 insulin
genes, Ins1 and Ins2 (Figure 3C &3D) that have shown
high gene expression differences in the arrays [see Addi-
tional File 3]. Similar trends of gene expression differences
between the two sets of samples, in the arrays and in the
Real time PCR were observed (Figure 3A-D).
Expression of insulin genes in the PLN was not expected
since insulin is synthesized, stored and secreted by the β
cells of the pancreatic islets in a highly regulated manner
in human and mouse. However ectopic expression or so-
called illegitimate transcription of self-antigens has been
previously reported, mainly in the thymus [28] and spleen
[29]. Cells expressing pancreatic autoantigens are also
found in peripheral lymphoid tissues and the same cell
can express more than one self antigen [15,30]. The func-
tional significance of these observations has been ques-
tioned and evidence from studies in the mouse strongly
suggested that self-antigen-expressing cells, in the thymus,
may participate in negative selection and mediate tolero-
genic signals, some of which may culminate in the apop-
totic death of autoreactive lymphocytes [31].
Considering this data, we have stained NOD PLN with
anti-insulin antibodies by immunohistochemistry (Figure
3F) and used pancreas as positive control (Figure 3E).
Sparse distribution of insulin expressing cells was noted in
the PLN (Figure 3F), while no staining has been obtained
in inguinal lymph nodes used as negative controls (Figure
3G), thus confirming the ectopic insulin gene expression
observed in our data. It is interesting to note that insulin
genes have been also found expressed in the PLN of NOD
mice at 4 weeks in a recent publication [32] although at
lower levels.
Noteworthy that except insulin no other endocrine-spe-
cific transcripts (somatostatin, glucagon, somatostatin
receptor or Islet amyloidal polypeptide) have been identi-
fied in our data set [see Additional File 4]. As expected and
similarly to the endocrine specific transcripts, no other
transcripts known to be specific either only to the exocrine
pancreas or to the developing pancreas were expressed in
the PLN at 5 weeks [see Additional File 4]. While expres-
sion of insulin genes in the PLN is not a novel finding, the
high levels of expression found in the PLN of E-IAA posi-
tive NOD mice was not expected and is bewildering. One
explanation might be that in the E-IAA positive PLN, APCs
expressing insulin might act, locally in the PLN, as insu-
lin-presenting cells. This would contribute to lack of toler-
ance to this molecule and consequently to the instigation
of insulin autoreactive lymphocyte trafficking, leading to
infiltration of the islets resulting to T1D. However a role
of insulin in local tissue architecture, independent of its
autoantigen function, cannot be excluded.
Transcriptional signatures specific to E-IAA sub-phenotype
An important aspect of our experimental design concerns
the early selection of NOD mice by the presence of E-IAA,
used as a marker of early autoimmune activity, at an age
whereas homeostatic changes in the pancreas might take
place. It has been demonstrated that increased neonatal
beta cell apoptosis is taking place with a peak at 2-3 weeks
after birth, in T1D animal models including the BB rat and
the NOD mouse [33]. The cross-talk between the pancreas
and the adjacent LN during or immediately after this
phase might be reflected by discrete gene expression
changes in this later tissue.
We undertook a series of exploratory functional data anal-
ysis aiming to comprehend the roles of the identified gene
expression variations in E-IAA-dependant islet autoimmu-
nity. Forty-one out of the 119 up-regulated genes showed
differential expressions over 5 fold [Additional File 3].
This indicates that the autoimmune process as reflected by
the presence of IAA in the positive NOD mice is marked
by local gene expression changes in the PLN. This might
include changes in the immune process, occurring in this
lymphoid tissue and/or changes in local tissue architec-
ture and remodelling, not only of the lymph node but
also of the pancreas, as mentioned above, assisted or
mediated by the genes expressed in the PLN.
i. Cellular compartment localization
An over representation of genes coding for extracellular
proteins has been identified as 38% (62/165) modulated
genes belonged to this category (P-value = 8.49E-16)
(Table 2). This does not seem to be a random distributionBMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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Hierarchical clustering representation of differentially expressed probe sets between E-IAA positive and negative PLN samples Figure 2
Hierarchical clustering representation of differentially expressed probe sets between E-IAA positive and nega-
tive PLN samples. Log2 transformed data from 177 probe sets are represented in a matrix format wherein each row displays 
expression results for a single gene across the arrays and each column shows the relative expression levels for all the genes in 
each sample. Red represents relative expression greater than the median expression level across all samples, and green repre-
sents an expression level lower than the median expression level. The colour intensity represents the magnitude of the devia-
tion from the median. The dendrogram at the left lists the genes and provides a measure of the relatedness of their expression 
profile in each sample. *Sample A36.4 corresponds to E-IAA negative phenotype despite its clustering according gene expres-
sion with the E-IAA positive samples (see also Table 1).BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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Validation of expression patterns of selected genes differentially expressed in the PLN of NOD mice Figure 3
Validation of expression patterns of selected genes differentially expressed in the PLN of NOD mice. A and B: 
Reg2 and Reg3a genes (A: Real Time PCR and B: arrays row data). C and D: Ins1 and Ins2 genes (C: Real Time PCR; D: arrays 
row data). Samples are PLN RNA from E-IAApos mice (A9.6 & A15.4) and from E-IAA neg mice (A12.2 & A8.1). E, F &G. 
Staining of histological sections with anti-Insulin antibodies, from pancreas (E), PLN (F) and Inguinal lymph nodes (G) from 
NOD mouse at 5 weeks.
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Table 2: Annotations chart report for over-representation of functional categories.
UP & DOWN REGULATED
GO CATEGORY/Term Gene Count (Ease score P-value)
Cellular compartment
Extracellular region 60 (9E-22) ↑, 2 ↓
Endoplasmic reticulum 11 (0.02) ↑
Nuclear 8↑ 6 (0.02) ↓
Organelle 35↑, 18 (0.03) ↓
Mitochondrion 10 (0.04) ↑
Molecular function
Catalytic activity 65 (1.4E-5) ↑, 9 ↓
Hydrolase 41 (8.9E-8) ↑, 3 ↓
Peptidase activity 27 (2.9E-10) ↑ 1 ↓
Serine-type peptidase activity 25 (8.3E-19) ↑
Actin binding 15 (8.2E-4) ↑ 7 (0.02) ↓
Calcium binding ** 10 (NS) ↑
Vitamin binding 6 (0.0008) ↑
Transferase NO- 3 (0.05) ↑, 3 ↓
Antigen binding** 5 (3.6E-4) ↓
Tissue kallikrein activity 8 (8.5E-12) ↑
Elastase activity 2 (2.5E-2) ↑
Biological process
Metabolic process 74 (6.4E-4) ↑, 17 (0.02)
Immune-related process** 68a ↑ 14 (3.6E-6)
Proteolysis 27 (1.5E-11) ↑
Cell structure** 26 (0.02) ↑
Lipid, Fatty acid & steroid metabolism** 15 (1.31E-4) ↑
mRNA transcription regulation** 22(0.09) ↓
Cell communication** 9 (0.05) ↑
Digestion 8 (3.73E-8) ↑
Cellular homeostasis 7 (0.01) ↑
IMMUNE-RELATED PROCESS**
B-cell & Antibody-mediated immunity** 9 (1.2E-4) ↓
Response to stress 18 (8.3E-5) ↑ 2.3E-2↓
MHC-I-mediated Immunity** 16 (0.09) ↑
Immunity & Defense** 16 (0.03) ↑ 4 (0.2) ↓
MHC-II-mediated Immunity** 15 (0.002) ↑
Response to external stimulus 14 (4.9E-5) ↑, 6 (0.5) ↓
Response to wounding 10 (5.09E-4) ↑
Inflammatory response 8 (0.001) ↑
Cytokine & chemokine mediated signaling
pathway** 7 (0.06) ↑
Other Immune defense** 7 (0.05) ↑
Humoral Immune response 4 (2.2E-3) ↑
Antigen presentation 3 (1.1E-2) ↓
Lymphocyte-mediated immunity 3 (0.008) ↓
Adaptive Immunityb 3 (0.008) ↓
The most relevant GO [23] and PANTHER [38] terms associated with the list of 165 E-IAA modulated genes are shown. Gene counts are the 
number of genes in the list at the corresponding term and arrows indicate up and down-regulated gene expression. P-value is a modified Fisher 
exact P-value, Ease score. Graphical representations of functional categories are shown on Figure 4. The list of all genes is available in Additional File 
5.
** PANTHER annotations
a Significance for combined annotation from GO (EASE): 8.35E-5<p < 0.07 and from PANTHER tool: 0.002<p < 0.09.
b Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin super family domainsBMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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since the first array of the MG-UG74Av2 series contains
2,057 transcripts coding for secreted proteins in a total of
12,488, representing 16% of the total number of genes on
the arrays. Moreover this class of proteins is overrepre-
sented in the E-IAA positive list of genes in the PLN (Fig-
ure 4a). The majority (30/41) of the over 5 fold expressed
genes in the up-regulated samples, code for secreted pro-
teins (GO P-value = 3.46E-22). This might reflect the cross
talk taking place between the PLN and the pancreas, dur-
ing the pre-inflammatory stages. Moreover secreted and
membrane-associated proteins are an important class of
proteins, as they have the potential to be detected in bio-
logical fluids and thus may be potential diagnostic mark-
ers or therapeutic targets.
Genes coding for secreted proteins include the Spp1 gene
coding for osteopontin that has been found to play also a
role in autoimmune demyelinating disease (MS) in
human [34]. High levels of this pro-inflammatory
cytokine have been reported in active relapsing-remitting
MS patients [35]. Several other genes coding for secreted
proteins with an immune/inflammatory function, include
kallikreins genes (Klk1b22, Klk1b9, Klk1b5, KlK1rb9,
Klk1b1, Klk16) that have been described as potential
biomarkers for certain cancers [36]. Members of the kal-
likrein large family that belongs to serine-type proteases
have been implicated in autoimmune diseases, in particu-
lar in a model of Sjögren's syndrome [37].
In contrast to the high representation of secreted proteins
coding genes, nuclear proteins transcripts are more rare in
our data set, representing 11% of the total number of the
modulated genes (18/165) (Figure 4a). This could indi-
cate that the high levels of mRNA found in the E-IAA pos-
itive PLN reflect a natural steady state process of gene
transcription, initiated prior to 5 weeks and/or regulation
of the mRNAs is taking place at the post transcriptional
level.
ii. Functional significance of the PLN gene signatures
Aiming to correlate relevant functions of our transcrip-
tome data with the E-IAA sub-phenotype and the end T1D
phenotype, we assessed for functional significance of the
identified genes. We applied two different approaches:
first the identified differentially expressed genes between
E-IAA positive and negative NOD mice have been sub-
jected to Gene Ontology analysis (GO, EASE) [23] and
evaluated for classification according to functional anno-
tations for over-representation, in combination with
assessment by PANTHER terms resource [38]. Thus in
each category are included not only genes belonging to
known functional categories by GO terms but also genes
for which annotations are attributed by existing published
experimental evidence together with consideration of evo-
lutionary relationships (PANTHER).
In this analysis, terms with the highest levels of signifi-
cance have been retained (for GO 8.35E-5<p < 0.07 and
for PANTHER 1.2E-4<p < 0.02). Several genes have been
annotated to Immune related process (Table 2) and sev-
eral belong to the serine proteases group and include
inflammation and immune functions (Table 2) and [see
Additional File 5]. This group of proteins is characterized
by the presence of a serine in the catalytic domain that is
highly conserved between its members. Disorders of the
dynamic balance of proteases and their inhibitors have
been reported in the blood stream and in lymphocytes of
diabetes patients and it has been proposed that increase of
proteases concentrations represents an early marker of
T1D [39]. Imbalance of the proteolytic system might also
change the local homeostasis and interfere with the extra-
cellular matrix of cells in the pancreas that become more
permissive to lymphocyte invasion as it has been reported
for tumour metastasis [40]. Further experimental evidence
is required in order to comprehend the significance of the
presence of serine proteases in the PLN of NOD mice.
Concerning the relevant distribution of functions
between up- and down regulated gene lists, it is to be
noted the presence of the serine-type proteases coding
transcripts, found only in the up-regulated list (Figure
4b). In contrast, 5 antigen binding genes were all down-
regulated in the E-IAA positive animals. Several immu-
noglobulin genes, including genes coding for the constant
region of the kappa chains and the lambda variable region
1 are in this category as well as the Cd1d1 antigen (Table
3). Cd1d1 plays a critical role in the positive selection of
T cells that produce Il-4 [41]. It has been reported that CD-
1 reactive NKT cells are required for the development of
systemic tolerance and defects of NKT cells affect autoim-
munity [42,43]. NKT cells while they enhance the
response to some bacterial, viral and parasitic infections
and they play a similar role in some types of cancer, yet
can suppress autoimmune disease, allograft rejection and
graft-versus-host disease [44]. Therefore up-regulation of
the Cd1d1 molecules in the E-IAA negative lymph nodes
might prevent the development of autoimmunity via its
binding to NKT-TCR. This can lead to expression of Il-4 by
NKT cells [45]. Il-4 is known as a Th2 cytokine and there-
fore protective for T1D [2]. A similar protective mecha-
nism has been described for experimental autoimmune
encephalomyelitis (EAE), considered to be the prototype
autoimmune disease mediated by type 1 helper T (Th1)
cells, in the mouse [45].
In a second approach we used literature mining together
with Ingenuity functional annotation tool (Ingenuity®
Systems). Combination of the resulting functional anno-
tations for all the genes in the list [see Additional File 6]
allowed assignment of more than one biological function
to certain genes and gave an overall classification in twelveBMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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Functional annotation for up- and down-regulated genes Figure 4
Functional annotation for up- and down-regulated genes. Functional categories distribution are according to GO and 
PANTHER annotations. a. Cellular component, b. Molecular function and c. Biological process. Significance for functional cat-
egories retained was 8.3E-19<p < 0.02 (* P-values ≤ 0.05). The gene list and corresponding P-values from each category are 
represented on Additional File 5.
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main functional categories (Table 3). Genes that did not
clearly belong to any of the categories were classified
together with ESTs, as 'unknown' and comprised less than
12% of the modulated genes (Table 3). In our data set
ESTs represented 7% of the identified genes, while in the
chips, unknown expressed sequences represent approxi-
mately 50% of the 12,486 probe sets spotted
(MG_U74A_v2 arrays).
Several transcripts belonged to more than one category
(Table 3 and Additional File 6). Given the essential role
attributed to the PLN in the activation of islet-specific
immune response [46], it was assumed, at this pre- or
peri-inflammatory stage (5 weeks of age) in the NOD
mice, that several chemokines or adhesion molecules
would be modulated in the autoantibody positive mice.
However this has not been the case. While several inflam-
matory mediators were consistently expressed in all PLN
from E-IAA positive and negative mice, few of these mol-
ecules were expressed in a significantly regulated manner
(data not shown). This concerned genes coding for several
chemokines (CCR7, CXCl12, CCR5, CXCl13, CCl21a and
CXCl9) that although gave present calls (P) to all samples,
did not meet statistical criteria for significant differences
between the two groups (data not shown). One hypothe-
sis might be that although all NOD mice possess the nec-
essary requirements (i.e. presence of several chemokines
in all samples) for the initiation of the inflammatory proc-
Table 3: Putative functional categories of transcriptional signatures in E-IAA positive versus E-IAA negative PLN
Putative Function Genes up-regulated* Genes down-regulated*
Inflammation/Infection Reg2, Reg1, Try4, Pap, Tff2, Klk1, Try10/Try4, 
Reg3a, Klk1b22, Klk1b9, Klk1b5, KlK1rb9, Klk1b1, 
Cuzd1, Pla2g1b, Mt1, Nupr1, Mt2, Spp1, Klk1b16, 
Krt18, Ahsg, Krt8, Vtn, Klk1b5, Plg, Klk1b26, Klk1b4, 
S100a9, Reg3γ, Hspa1a, Retn, S100a8, Slc23a3, Ghr
Immune function Spp1, Rnase 1, Sycn, Dmbt1, Ela1, Ela2A, Egfbp2, 
Ang, Fga, Crlf1, Crlf2, C1qb, Rnase4, Cfd, Ctrl, Gc, 
Egf, Ngp
Ighg, Igl-V1, AI324046/IgG1c, Rap1a, Ms4a6b, Crlf3, 
Cd55, Ctla2b, Cd1d1, Myo5a, Cd74, Cr1/Igk-C, 
LOC100046793 similar to IgkV28
Cell death and apoptosis Rnase1, Ins2, Alb, Mt1, Nupr1, Mt2, Spp1, Muc1, 
Krt18, Hba-a1, Ins1, Hpn, Krt8, Vtn, Plg, Alas2, Gjb2, 
Egf, Lrpap1, Gstz1, Ptger3, Fzd3, S100a9, Dsp, Hspa1a, 
Aass, S100a8, Hbb-b2, Ghr, Zbtb16, Cyp2e1
Pcna, Cd55, Hnrpc, Cd1d1, Cd74, Oaz1, Eef1a1
Cancer Prss3, Prss2, Dmbt1, Tff2, Mt1, Nupr1, Mt2, Spp1, 
Muc1, Ggh/LOC667301, Arhgdig, Tmem97, Itih4, 
Cyp3a11, Ang, Krt18, Gc, Ahsg, Sel1l, Hpn, Vtn, 
Actb, Plg, Gjb2, Egf, Lrpap, Lpl, Asns, Fzd3, S100a9, Dsp, 
Lcat, Acta2, Tmem56, Rhou, Ndrg2 similar, Ces3, S100a8, 
Ghr, Zbtb16, Tmem30b, Cyp2e1
Hmgn1, Top2b, Rap1a, Usp1, Pcna, Cd55, Cd1d1, Rps3, 
Cd74, Oaz1
Cell-cell signalling Prss2, Ins2, Reg3a, Ins1, Alb, Spp1, Ang, Krt18, Gc, 
Fga, Krt8, Vtn, Plg, Egf, Lrpap1, Lpl, Ptger3, S100a9, 
Acta2, S100a8, Ghr
Cd74, Cd1d1, Cd55
Cell movement Prss3, Ins2, Tff2, Ins1, Cckar, Pla2g1b, Spp1, Muc1, 
Ang, Gc, Fga, Sel1l, Hpn, Vtn, Actb, Plg,, Ctrb1, Gjb2, 
Egf, Lrpap1, Aldh1a7, S100a9, Lcat, S100a8, Zbtb16
Nde1, Top2b, Cd55
Diabetes Pnliprp1, Amy2-1, Ins2, Cel, Clps, Ins1, Amy1, 
Pnliprp2, Alb, Fkbp11, Rbp4, Mod1, Cpn1
Regeneration & Remodelling Reg2, Reg1, Pap, Reg3a, Spp1, Itih4, Hbb-b2, Hba-
a1, Itih2, Reg3γ, Ptger3, Zbtb16
Evi2a, Oaz1
Organizational injury Mt1, Nupr1, Mt2, Spp1, Krt18, Hbb-b2, Krt8, Vtn, Plg, 
Egf, Lrpap1, Gstz1, Lpl, S100a9, Dsp, Acta2, Cyp2e1
Cell organization Ins2, Ins1, Pla2g1b, Mt1, Mt2, Spp1, Krt18, Krt8, 
Vtn, Egf, Dsp, Rhou, Ghr
Nde1, Rap1a, Myo5a
Ubiquitination Fkbp11, Sel1l Znrf2, Hnrpc, Hnrpr, Usp1, Trim59, Ube2e1
Transcription Nupr1, Ang, Pcbd1, Hbb-b2, Rnase4, Foxa3, Zbtb16 Hmgn1, Spic, Sp4
Other Nucb2, Olfr93, Car3, Ero1lb, Pah, Gcat, Gv-1, Copz2, 
Cdo1, Xist, Pck1
Slx/Xmr, Slain1, Acsl4
Unknown/EST AI593999, AE000663, Cckar, 1810009J0RIK, 
Arhgdig, Gnmt, Pcbd1, M26005, AV171666, Gamt, 
AE000663, Gatm, Thrsp, AV250694, AW049643, 
AV067171
Gt(ROSA)26Sor, Pcid2, AA590345, AI842858, AI848107
Functional category annotations are considered significant with P-values < 0.05 as reported by Ingenuity Pathways Analysis software (IngenuityR 
Systems). Additional functions have been attributed to transcripts by literature data mining (see Additional File 6]. Transcripts are ordered 
according to levels of statistical significance for gene expression variation.* Genes with expression differences >2 fold are written in bold face font 
and normal font otherwise (1.5-2 fold).BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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ess against the pancreatic islets, the autoimmune-driven
destructive events are probably dependent upon the levels
of pancreatic tissue remodelling taking place. This in turn
could be due to either antibody bearing B cells (IAA) or T
lymphocyte specific trafficking against pancreatic signals.
Genome view of the transcriptome signatures
A genome view of our transcriptome data gave an unex-
pected image of chromosomal gene localization, pointing
to mainly two chromosomes that showed stretches with
the highest P-values containing >20 selected genes (Figure
5). This was the case for chromosome 6 (27 probe sets, p
= 1.31E-5) and chromosome 7 (23 probe sets, p = 0.025).
Two additional stretches on chromosome 10 and on chro-
mosome 17 around the MHC locus were also detected but
with a lower gene number.
Genes on the chromosome 6 are placed in 3 families
including the lithostatin family, immunoglobulin light
chain and several serine type proteases coding genes.
Genes on chromosome 7 concerned mainly the kallikrein
coding genes and the insulin-2 gene. Interestingly 4 T1D
Idd loci have been described on these two chromosomes
by genetic linkage analysis: two loci on mouse chromo-
some 6, the Idd6 [47] and Idd19 [48] and two Idd loci on
mouse chromosome 7: the Idd7 [49] and the Idd27 [50].
Discussion
Autoimmune diabetes in human is a heterogeneous disor-
der whereas several genes influence the apparent clinical
phenotype together with environmental factors and
homeostatic differences inherent to the organism. This
leads to phenotypic variations of the disease observed not
only in human but also in the NOD mouse, despite the
genetic homogeneity of this inbred strain. Indeed autoan-
tibody responses vary between individual mice by the tit-
ers and by the age of appearance. Similarly temporal
variation in the severity of the islet-damaging inflamma-
tory process is observed as well as variations in the onset
of appearance of the end point disease.
Genome image view of genes identified in the PLN transcriptome Figure 5
Genome image view of genes identified in the PLN transcriptome. Probe sets taken in consideration are the same as 
for hierarchical clustering (see Fig 2). In this "Genome view" genes in the gene list are coloured in black small vertical bars while 
the other genes are coloured in light-gray. The transcription starting site is used for gene position. The significant gene 
stretches are outlined in blue boxes and shorter stretches, when they exist, are contained within the longer ones that are indi-
cated (methodology used is as described in http://www.dchip.org).
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In the present study we used the early presence of IAA in
the NOD serum, as the earliest measurable sub-pheno-
type, aiming first to address for changes occurring in the
pancreas-draining lymph nodes, when the autoimmune
process has been just initiated. The PLN is a structured sec-
ondary lymphoid organ where pancreas derived cells and
signals are expected to be delivered. The resulting output
of the processing of these signals is either the maintenance
or the loss of pancreas integrity. Our second aim was to
attempt a stratification of disease check points by studying
the first possibly identifiable disease stage, as selected by
the presence of E-IAA.
This rational, potentially, allows identification of early
genetic components that due to their specific expression
in the PLN, at a precise time, may not be identified by
genetic studies whereas the final T1D phenotype is usually
taken in consideration.
Biological significance of the identified transcriptional 
signatures and relevance to T1D phenotypes
Phenotypic stratification, as delineated by sub phenotypic
attribution for the identification of gene expression varia-
tion in autoimmune diabetes, has not been used, to our
knowledge, prior to our study. Two recent reports have
also used PLN in a similar methodology approach, at early
ages in the NOD mice, without however prior phenotypic
evaluation [32,51]. One group studied 4 and 6 weeks old
NOD/BDC 2.5 mice [51], the other group used NOD mice
of various ages starting at 10 days and including 4 weeks,
to compare with NOD.B10H2b mice [32].
While our study has been carried out at 5 weeks of age it
differs from these former investigations by the experimen-
tal design, based on the E-IAA sub phenotypic animal
selection criteria. Accordingly, it can be assumed that gene
expression changes solely correspond to the phenotype
used for selection since the only perturbation, in our
design, is the presence of E-IAA. While we cannot exclude
that the identified gene profiles might correspond to the
more rapid, though still infra-clinical progression to T1D,
of the individual mice rather than to the E-IAA sub-phe-
notype, hierarchical unsupervised clustering (Figure 2)
indicates however that samples are not randomly distrib-
uted. As the genetic background and the ages of the ani-
mals are indeed identical, this gives the opportunity to
identify genes that might be activated in an autoimmune-
dependent manner in the NOD mice, after or around the
massive neonatal β cell apoptosis taking place [33]. It has
been suggested that β cell death throughout the early ages
in the NOD mice, may be an initial trigger for APC activa-
tion and the development of T1D [52]. Defects in silent
clearance of apoptotic remnants before necrosis might
prevent processes of the physiological maintenance of tis-
sue integrity to operate [53]. In the rat intestine a discrete
subpopulation of DCs has been found to transport apop-
totic remnants to T cell areas of the mesenteric LN [54].
Interestingly several transcripts expected to contribute to
physiological tissue remodelling were up-regulated in the
E-IAA positive list (Table 3 & Figure 6).
Tissue regeneration and remodelling
The expression of five genes belonging to the regenerating
islet-derived gene family (Pap,  Reg1, Reg3a, Reg3g  and
Reg2), implicated in tissue integrity, maintenance and
regeneration were highly up-regulated in our data set [see
Additional File 6]. They code for a set of related but dis-
tinct proteins [55]. The presence of these proteins in the E-
IAA samples is intriguing, especially in the light of recent
published reports demonstrating that adult human islets
possess a remarkable degree of morphogenetic plasticity
[56]. Similarly to Reg genes, Itih-4, a serine-type protease
inhibitor with anti-apoptotic and matrix stabilizing func-
tions, is also up-regulated and reported to play a role in
liver development and regeneration [57]. These transcrip-
tional signatures, if sorted out as such, might represent a
new tool in the understanding of islet neogenesis and tis-
sue preservation by inherent factors and could be valuable
against β-cell destruction.
Sustained inflammatory processes and tumour progression
Several of the modulated transcripts belong to complex
networks of gene products acting in tissues during inflam-
matory sustained processes (ie. Spp1, Klks, Mt2), or play-
ing a role in tissue regeneration (ie. Regs) and have been
found also to be associated with neoplasia (Table 3), [see
Additional File 6]. Certain kallikrein coding genes have
been up-regulated in our data set and are considered pos-
sible biomarkers for cancer [58]. Similar expression pat-
terns have been found for Muc1  gene that is highly
expressed in gastric carcinoma and proposed to be
involved in gastric carcinogenesis [59] as well as for the
genes Cckar, Ggh [60,61] and Ang [62] that were reported
to be implicated in the genesis of various tumours. Ang, in
particular, is involved in the Notch signalling pathway
related to neurovascular progression of pancreatic cancer
and metastasis [63], as well as in multiple myeloma [64].
It has been reported that circulating levels of angiogenic
cytokines can predict tumour progression and prognosis
in neuroendocrine carcinomas of the gastro-entero-pan-
creatic system [62].
Finally, the gene coding for nucleobindin 2 (Nucb2)
implicated in B cell lymphomas [65] was also up-regu-
lated. It is a DNA binding protein, called also NEFA and
its sequence contains a signal peptide, suggesting that it is
a secreted or trans-membrane protein [66].BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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Heat Map of signal intensities of gene expression patterns Figure 6
Heat Map of signal intensities of gene expression patterns. Genes found to be highly expressed in the E-IAA positive 
(yellow) negative (red) PLN according to functional annotations, as described on Table 3. The dendrogram, on the top of the 
figure, represents unsupervised hierarchical clustering of the samples, according to gene expression patterns. *Sample A36.4 
corresponds to E-IAA negative phenotype despite its clustering according gene expression with the E-IAA positive samples 
(see also Table 1). Functional annotations have been ordered manually.BMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
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Infection and inflammation
Several genes known to play a role in various inflamma-
tory conditions were differentially modulated in our data
set (Table 3). Such molecules include two elastase genes,
Ela1 [67] and the neutrophil elastase Ela2 [68], known to
play a role in peripheral tissues invaded by microbes [69],
the Spp1 gene [70], and the secretory granule protein syn-
collin (Sync), expressed by neutrophils with a role in host
defence to infections by invading bacteria, fungi, and pro-
tozoa [71]. Sync is also expressed in the exocrine pancreas
and in the duodenum and colon [72]. Other gene prod-
ucts operating during the inflammatory process include
the Egfbp2, part of the kallikrein gene family [73], the actin
binding protein (Actb), the mentioned above Muc1 that is
part of signalling proteins regulating cell adhesion/de-
adhesion [74] and two genes coding for metallothionein,
Mt1 and Mt2. Increased levels of Muc1 have been found in
the small intestine of a cystic fibrosis mouse model [75].
Over expression of metallothioneins has been described
in gastric cancer and in intestinal metaplasia and dyspla-
sia [76]. Mice lacking metalothionein are more suscepti-
ble to Helicobacter pylori colonization and gastric
inflammation, indicating a protective effect of these pro-
teins against H. pylori-induced gastritis [77].
Interestingly, several lipases coding genes that have been
associated with diabetes were up-regulated in the E-IAA
positive PLN (Table 3). Pla2g1b gene has been described
as a pro inflammatory molecule expressed in lung epithe-
lium hosting Pseudomonas aeruginosa [78]. It is also impli-
cated in glucose uptake by the liver, heart and muscle
tissues under high glucose diet [79]. Inhibition of lipase
activity was shown to reduce the incidence of type 2 dia-
betes mellitus and genetic variations in the Clps and Pnlip
genes are associated with type 2 diabetes [80].
Two additional genes coding for pancreatic lipase related
proteins Pnliprp1 and Pnliprp2 were highly up-regulated in
the E-IAA PLN (Table 3) and [see Additional File 3].
Pnliprp2 protein plays a crucial role in the digestion of
dietary fats in milk suckling mammals [81] while it seems
to participate in T cell cytotoxicity. A T cell lipase shares
74% amino acid identity with the pancreatic Pnliprp2
[82].
Could novel hypothesis be further explored in NOD mice 
at early post birth period?
Overall the data reported herein suggest that the events
leading to islet-damaging autoimmune destruction might
be rooted to early processes, some sharing common char-
acteristics with several other inflammatory conditions
found also in microbes-hosting tissues (i.e. Pla2g1b, Mt1)
and in certain cancers (i.e. Klk genes, Muc1, Reg genes).
Noticeably among the cytokine receptor-like factor 1 and
3 (Crlf1, Crlf3) that belong to the same family [83], Crlf3
has been found to be up-regulated in skin cancer [84].
While Crlf1 expression is up-regulated in the E-IAA posi-
tive samples, expression of the Crlf3 gene is down-regu-
lated. Crlf1 mRNA has been reported to be up-regulated
by TNF-α, IL-6, and IFN-γ [83]. Polymorphisms in the reg-
ulatory region of C1qb gene have been correlated with
down-regulation of the murin c1q protein levels and
linked to lupus nephritis [85].
The exact order of events in autoimmune initiation
requires additional studies in order to be elucidated. Our
hypothesis implies that defects in pancreas remodelling
processes, taking place at the weaning period, might be a
trigger for immune deregulation leading to autoimmune
tissue destruction. This might include tissue regeneration
or damage. The developmental stage of the organism as
well as agents exogenous to the organism, such as invasive
microbes, potentially can contribute to local homeostatic
changes. It can be assumed that the identified genes have
the potential to re-address the question of the link
between environmental triggers, such as sustained micro-
bial signalling processes, with the autoimmune process, at
least in T1D.
This hypothesis requires certainly additional integrative
studies and experimental evidence to be validated. It is
noticeable that none of the common pro-inflammatory
molecules such as tumour necrosis factor or interferons
have been found in our group of genes. It has been
recently reported 8 IFN-α inducible genes to be differen-
tially up-regulated in CD4+ T cells isolated from the PLN
of 6 wks, when compared with 2 weeks old NOD/BDC 2.5
mice [51]. These authors concluded that IFN-α initiates
T1D in the NOD mice and suggested that pDCs and TLRs
play a role in T1D initiation. Though NOD mice differ
from strains unable to initiate islet autoimmunity in
terms of their response to IFN, our data indicate that such
differences are not associated, within the NOD strain,
with early expression of IAA, which in its turn is associated
with greater risk of diabetes progression, at least at the age
studied in this report.
Conclusion
The autoimmune-related transcriptional early landscape
of the PLN, in a first glance, seems difficult to be con-
tained due to its complexity. The stepwise nature of the
process resulting in T1D, is illustrated in our study by the
difficulty to sort out a clear mechanism describing a pos-
sible scenario for disease initiation and implicating, pref-
erably, a small number of molecules. Nevertheless, the
gene signatures identified by this global analysis of the
PLN in the autoantibody positive NOD mice at 5 weeks,
together with the functional annotations described
herein, represent a valuable tool in designing additional
experiments for understanding the irreversible initiationBMC Medical Genomics 2009, 2:63 http://www.biomedcentral.com/1755-8794/2/63
Page 17 of 19
(page number not for citation purposes)
of the autoimmune process in T1D. Experimental investi-
gation of the functions of the identified genes together
with further integrative analysis studies have the potential
to sear light into the exact autoimmune-related processes
that take place at this early age, in autoimmune prone,
insulin autoantibody positive animals.
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